Nu-Med Plus(OTC) NUMD

Nu-Med Plus develops devices to deliver nitric oxide gas for hospitals and research labs. Its products aim to help patients with breathing problems and support medical studies. The company focuses on making these systems easier and cheaper to use for healthcare providers.

Gadgets in the Gas Lane: Nu-Med Plus’s Main Offerings

• Hospital nitric oxide system: Delivers inhaled nitric oxide to patients in intensive care units; 0% of revenue (pre-revenue).
• Clinical delivery unit: Provides nitric oxide in clinics and rehab centers; 0% of revenue (pre-revenue).
• Mobile rechargeable device: Battery-powered for use in remote or transport settings; 0% of revenue (pre-revenue).
• Disposable delivery unit: Single-use device for high-volume or emergency scenarios; 0% of revenue (pre-revenue).
• Research dilution system: Supplies high-purity nitric oxide for laboratory and investigational use; 0% of revenue (pre-revenue).

Growth Spurts and Stumbles: Expansion Moves

• No acquisitions or global market entries reported since founding in 2011.
• Product development suspended in 2025 pending new funding.
• Strategic focus on cost-saving, on-demand nitric oxide generation technology since 2023.
• Recent funding of $14,000 from company officers in July 2025 to cover expenses.

What Makes Nu-Med Plus Stand Out (Besides the Name)

Nu-Med Plus targets gaps in nitric oxide delivery by developing on-demand, portable, and disposable systems. Its approach aims to lower costs and simplify logistics for hospitals and labs. The company’s small size allows for focused innovation, but it faces significant funding and regulatory hurdles.

Five Things You Need to Know

• No revenue reported for any period through June 30, 2025.
• Operating loss improved 35.0% year-over-year to $-10,419 in Q2 2025.
• Net loss improved 32.5% year-over-year to $-11,665 in Q2 2025.
• Cash position was $863 as of June 30, 2025, with $254,857 in liabilities.
• Company is funded only through September 30, 2025, with substantial doubt about ongoing operations.

Bottom Line

Nu-Med Plus remains a pre-revenue medical device developer focused on nitric oxide delivery. Its future depends on securing funding and regulatory approval to move products to market.